Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Honolulu, Hawaii 96813


Purpose:

This study is being conducted to provide initial safety, tolerability, PK and PD data that will allow further studies with darapladib in Japanese patients


Criteria:

Inclusion criteria: - Japanese males, 20-64 years of age, inclusive - Body weight >50Kg - Body Mass Index (BMI): 18-28 - Subjects must have lived outside of Japan no more than 10 years - Non-smoker or smokes fewer than 10 cigarettes/day Exclusion criteria: - History of asthma, anaphylaxis or anaphylactoid reactions, severe allergic responses - History of sensitivity to heparin or heparin-induced thrombocytopenia - History of alcohol/drug abuse or dependence within 12 months of the study - Positive syphilis, HIV antibody, Hepatitis B, Hepatitis C - History of cholecystectomy or biliary tract disease or history of liver disease - Participation in a clinical study within 30 days prior to first dose - Subject has been exposed to more than 4 chemical entities within 12 months - Positive urine drug and alcohol at screening - Subject has any medical history or clinically relevant abnormality that would make the subject ineligible for inclusion due to safety reasons.


NCT ID:

NCT00551317


Primary Contact:

Study Director
GSK Clinical Trials
GlaxoSmithKline


Backup Contact:

N/A


Location Contact:

Honolulu, Hawaii 96813
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: August 20, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.